查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971603

5α-还原酶缺乏症市场：依治疗方法、剂型、给药途径、年龄层、通路和最终用户划分－2026-2032年全球预测

5-Alpha Reductase Deficiency Market by Treatment Type, Formulation, Route Of Administration, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 5α-还原酶缺乏症市场在 2025 年的价值为 14.1 亿美元，在 2026 年成长到 15.6 亿美元，到 2032 年达到 29.8 亿美元，复合年增长率为 11.25%。

主要市场统计数据
基准年 2025 14.1亿美元
预计年份：2026年 15.6亿美元
预测年份 2032 29.8亿美元
复合年增长率 (%) 11.25%

针对 5α-还原酶缺乏症的现代治疗方法，制定了清晰、权威的临床、治疗和医疗保健系统方面的指南。

本执行摘要概述了5α-还原酶缺乏症的临床、科学和商业性方面。 5α-还原酶缺乏症是一种罕见的酵素失调疾病，会影响雄性激素代谢，并带来复杂的诊断和治疗挑战。引言部分首先从三个观点来阐述：遗传和生化病理病理学、现代治疗方法和治疗流程，以及不断发展的医疗保健系统如何影响病人就医和临床医生的决策。透过将临床实际情况与分销和监管因素相结合，引言部分旨在帮助相关人员评估研发和商业化方面的策略重点。

诊断技术的进步、药物配方的创新以及分销模式的转变正在全面重新定义治疗途径和商业策略。

5α-还原酶缺乏症的治疗格局瞬息万变，药理学、诊断技术和患者参与这三大力量正共同重塑治疗模式。分子层面的深入研究和诊断流程的改进缩短了许多患者的确诊时间，而药物科学的创新和给药途径的拓展则提高了治疗的效用和耐受性。同时，真实世界证据和病人报告结局的累积正在影响处方医生的选择，加速了从标准化治疗方法到个人化治疗方案的转变。因此，那些投资于实证医学和差异化产品的公司和医疗机构能够更快地对临床实践产生影响。

评估美国在 2025 年实施的关税措施将如何影响供应链重组、采购方式调整和价格策略调整。

美国2025年实施的关税措施对全球供应链、筹资策略以及与5α-还原酶缺乏症治疗相关的成本结构产生了多方面的影响。药品原料和成品的关税调整迫使製造商重新评估其筹资策略，一些製造商加快了近岸外包和策略供应商多元化的步伐，以降低跨境成本波动带来的风险。这种调整将立即影响前置作业时间、库存管理以及国产製剂和进口製剂之间的竞争格局。

详细的細項分析揭示治疗类型、製剂形式、给药途径、分销管道、最终用户环境和年龄层如何影响策略决策。

详细的细分检验揭示了不同治疗方法、製剂形式、给药途径、分销管道、终端用户环境和年龄组之间存在的机会和限制因素。按治疗方法划分，该治疗领域以度他雄胺和非那雄胺等药物为特征，每种药物都具有独特的药物动力学特征、专利历史和临床医生熟练程度，这些都会影响处方行为和生命週期管理策略。这些差异与剂型选择密切相关。基于剂型的市场分析将药物分为胶囊、溶液和片剂。胶囊有缓释和速释两种类型，溶液分为浓缩型和标准型，而片剂则有缓释和速释两种设计。剂型差异不仅影响疗效和依从性，还会影响生产复杂性和监管路径。

一项比较区域分析，重点关注全球主要全部区域。

区域趋势对5α-还原酶缺乏症治疗药物的临床应用、监管路径、报销机制和分销策略有着深远的影响。在美洲，主要市场监管的协调统一以及专科医疗机构的集中，正推动差异化製剂和病患支援计画的快速上市。同时，与支付方的谈判动态以及保险覆盖范围的多样性，也影响药物的取得途径和最终价格。此外，区域内的跨境供应链因素也会影响采购决策和库存策略。

决定永续领导地位的关键竞争优势包括：产生临床证据、製造韧性、通路伙伴关係和生命週期管理。

5α-还原酶缺乏症领域的竞争格局取决于研发的策略优先顺序、製造地的选择以及提供综合患者支援的能力。投资可靠的临床证据（包括长期安全性数据和患者报告结果）的公司将赢得专家和付款方的信任。同样，那些建立能够优化速效製剂（用于快速调整剂量）与缓释製剂/外用製剂（用于提高用药依从性和耐受性）之间平衡的製剂组合的公司，可以在临床和商业上脱颖而出。

切实可行的综合建议，涵盖证据产生、供应链韧性、配方差异化、分销管道协调和相关人员参与，以确保竞争优势。

行业领导者应推动一系列合作倡议，将临床进展转化为可持续的商业性优势，同时确保药物的可及性和供应。首先，应优先投资于能够同时反映临床疗效和真实世界结果的证据生成。可操作的临床试验和註册数据能够影响处方集决策和临床医生的采纳。其次，应实施供应链多元化措施，包括近岸外包、确保多家认证供应商以及灵活的生产合同，以降低关税和物流风险。这些营运倡议将降低政策变化带来的风险，并提高对需求波动的应对力。

为了检验本报告中提出的策略见解，我们采用了严谨的混合调查方法，该方法结合了对临床医生的访谈、供应链专家的见解、文献分析和情境分析。

本报告的调查方法结合了定性和定量技术，以确保研究结果的可靠性和可重复性。主要研究包括对皮肤科医生和泌尿系统进行结构化访谈，与供应链和监管专家进行讨论，以及对分销管道相关人员进行访谈。这些工作旨在直接观点临床决策因素、采购惯例和病患就医障碍，使分析立足于真实世界经验。

一项策略整合，强调临床、营运和政策因素的融合，这些因素将决定未来获得这种罕见内分泌疾病治疗方法的机会和价值创造。

总之，5α-还原酶缺乏症领域的格局正在发生变化，这种变化有利于在临床开发、生产、分销和医保支付方参与方面开展策略合作。基因和诊断技术的进步、製剂的创新以及分销模式的转变正在重塑治疗方法的开发、交付和应用方式。同时，诸如关税调整和医保支付方谈判等政策措施要求各机构在采购和合约决策方面保持灵活，以确保药物的可及性和盈利能力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：5α-还原酶缺乏症市场及治疗方法

  • 度他雄胺
  • 非那雄胺

第九章 依配方分類的5α-还原酶缺乏症治疗药物市场

  • 胶囊
    • 缓释製剂
    • 立即发布
  • 解决方案
    • 浓缩型
    • 标准
  • 药片
    • 缓释製剂
    • 立即发布

第十章：5α-还原酶缺乏症市场：依给药途径划分

  • 口服
  • 外用

第十一章：5α-还原酶缺乏症市场：依年龄组别划分

  • 成人版
  • 老年人
  • 儿童

第十二章：5α-还原酶缺乏症市场：依通路划分

  • 医院药房
    • 私人的
    • 民众
  • 网路药房
    • 品牌入口网站
    • 第三方市场
  • 零售药房
    • 链
    • 独立的

第十三章：5α-还原酶缺乏症市场：依最终用户划分

  • 诊所
    • 皮肤科
    • 泌尿系统
  • 居家照护
    • 由看护者管理
    • 自我管理
  • 医院
    • 一般的
    • 专科医院

第十四章：5α-还原酶缺乏症市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：5α-还原酶缺乏症市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 5α-还原酶缺乏症市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国5α-还原酶缺乏症市场

第十八章：中国5α-还原酶缺乏症市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cadila Healthcare Limited
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2B5802CFE14D

The 5-Alpha Reductase Deficiency Market was valued at USD 1.41 billion in 2025 and is projected to grow to USD 1.56 billion in 2026, with a CAGR of 11.25%, reaching USD 2.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.41 billion
Estimated Year [2026] USD 1.56 billion
Forecast Year [2032] USD 2.98 billion
CAGR (%) 11.25%

A clear and authoritative orientation to the clinical, therapeutic, and health-system dimensions shaping modern responses to 5-alpha reductase deficiency

This executive summary introduces the clinical, scientific, and commercial contours of 5-alpha reductase deficiency, a rare enzymatic disorder that influences androgen metabolism and presents complex diagnostic and management challenges. The opening frames the condition through three lenses: genetic and biochemical pathophysiology, contemporary therapeutic modalities and treatment workflows, and the evolving health-system context that shapes patient access and clinician decision-making. By situating clinical realities alongside distribution and regulatory factors, the introduction prepares stakeholders to evaluate strategic priorities across research, development, and commercialization.

Subsequent sections build on this framing by detailing shifts in therapeutic innovation, supply chain and policy influences, segmentation-driven adoption dynamics, and practical recommendations for industry leaders. Transitional commentary highlights how advances in pharmacology and patient-centered care are altering traditional approaches, while emphasizing the need for integrated responses from manufacturers, payers, and providers to optimize long-term outcomes for affected patients.

How diagnostic advances, formulation innovations, and shifting distribution paradigms are collectively redefining treatment pathways and commercial strategies

The landscape for 5-alpha reductase deficiency is in flux, driven by converging forces in pharmacology, diagnostics, and patient engagement that are redefining treatment paradigms. Molecular insights and improved diagnostic pathways are shortening time-to-diagnosis for many patients, while innovations in formulation science and route-of-administration options are expanding therapeutic utility and tolerability. At the same time, real-world evidence generation and patient-reported outcomes are informing prescriber preferences, encouraging shifts from one-size-fits-all regimens to more individualized treatment plans. Consequently, companies and health systems that invest in evidence generation and differentiated product delivery are positioned to influence clinical practice more rapidly.

Parallel to clinical changes, commercial dynamics are being reshaped by distribution channel diversification and digital health adoption. Increasing use of telemedicine and online pharmacy platforms is altering how patients obtain medications, which in turn affects adherence, monitoring, and support programs. Regulatory agencies are also adapting frameworks to accommodate novel formulations and generics, placing a premium on robust pharmacovigilance and lifecycle management. Overall, these transformative shifts create both opportunity and obligation: stakeholders who proactively align R&D, manufacturing, and commercial strategies with these changes will benefit from improved patient outcomes and more resilient market positioning.

Assessing supply chain reconfiguration, procurement adaptations, and pricing strategy recalibrations driven by U.S. tariff measures enacted in 2025

Recent tariff actions implemented in the United States in 2025 have had multifaceted implications for the global supply chain, procurement strategies, and cost structures relevant to therapies used in managing 5-alpha reductase deficiency. Tariff adjustments on pharmaceutical inputs and finished products have encouraged manufacturers to re-evaluate sourcing strategies, with some accelerating nearshoring efforts and strategic supplier diversification to reduce exposure to cross-border cost volatility. This repositioning has immediate implications for lead times, inventory management, and the relative competitiveness of domestic versus imported formulations.

Moreover, tariffs have catalyzed shifts in pricing strategies and contract negotiations between manufacturers and major payers. Health systems and large pharmacy chains are responding by seeking longer-term procurement agreements and more transparent cost-of-goods disclosures. In parallel, regulatory and customs processes are receiving greater attention to limit disruptions; companies are investing in compliance capabilities and scenario planning to mitigate supply interruptions. Importantly, these dynamics have also impacted research and development decisions: organizations are recalibrating production footprints, prioritizing modular manufacturing investments, and assessing how tariff-related costs influence margin expectations and product accessibility. Taken together, the cumulative impact of tariff policy changes underscores the need for integrated operational resilience and proactive policy engagement.

Detailed segmentation analysis illuminating how treatment types, formulations, administration routes, distribution channels, end-user settings, and age cohorts drive strategic decisions

A granular examination of segmentation reveals distinct opportunities and constraints across treatment modalities, formulations, administration routes, distribution channels, end-user settings, and age cohorts. Based on Treatment Type, the therapeutic landscape is characterized by agents such as Dutasteride and Finasteride, each presenting different pharmacokinetic profiles, patent histories, and clinician familiarity that inform prescribing behavior and lifecycle management strategies. These differences intersect with formulation choices; Based on Formulation the market is parsed into Capsule, Solution, and Tablet formats, where Capsules include Extended Release and Immediate Release variants, Solutions are evaluated as Concentrated and Standard presentations, and Tablets are available in both Extended Release and Immediate Release designs. Formulation differentiation influences not only efficacy and adherence but also manufacturing complexity and regulatory pathways.

Route-of-administration considerations further refine product positioning; Based on Route Of Administration oral and topical options present divergent trade-offs in systemic exposure, convenience, and monitoring requirements. Distribution channel segmentation shapes access and patient experience; Based on Distribution Channel treatments move through Hospital Pharmacy environments split between Private and Public institutions, Online Pharmacy venues where Branded Portals coexist with Third-Party Marketplaces, and Retail Pharmacy networks differentiated by Chain and Independent outlets. These channels affect patient outreach, specialty support, and reimbursement engagement. End-user segmentation underscores care delivery nuances; Based on End User clinics-subdivided into Dermatology and Urology clinics-home care settings that are Caregiver-Administered or Self-Administered, and hospital contexts including General and Specialty units each demand tailored service models. Age-group distinctions also matter; Based on Age Group the needs and safety considerations for Adult, Geriatric, and Pediatric patients vary substantially, guiding dosing strategies, monitoring protocols, and formulation preferences. Integrating these segmentation layers enables nuanced product development, commercialization planning, and patient support designs that align with clinical realities and channel dynamics.

Comparative regional analysis focused on regulatory complexity, payer heterogeneity, and localized commercialization strategies across all major global territories

Regional dynamics exert a profound influence on clinical adoption, regulatory pathways, reimbursement frameworks, and distribution strategies for therapies addressing 5-alpha reductase deficiency. In the Americas, regulatory harmonization across large markets and a concentration of specialty care providers support rapid adoption of differentiated formulations and patient support programs, while payer negotiation dynamics and insurance coverage heterogeneity shape access pathways and price realization. Cross-border supply chain considerations within the region also influence sourcing decisions and inventory strategies.

Across Europe, Middle East & Africa, divergent regulatory regimes and heterogenous health-system structures require bespoke market entry plans that account for national reimbursement processes and variable clinician experience with rare endocrine conditions. Tailored evidence packages and local clinical engagement are often necessary to build prescriber confidence. In the Asia-Pacific region, diverse healthcare infrastructures and rapidly evolving pharmaceutical manufacturing capacity present both opportunities for scale and challenges in ensuring equitable access. Growing domestic production capabilities, expanding specialty clinic networks, and increasing digital health adoption all contribute to a dynamic environment where partnerships and localized commercialization models can accelerate reach. Recognizing these distinct regional characteristics is essential for designing pragmatic, compliant, and culturally informed strategies for product rollout and patient support.

Critical competitive levers including clinical evidence creation, manufacturing resilience, channel partnerships, and lifecycle management that determine sustained leadership

Competitive dynamics in the 5-alpha reductase deficiency space are shaped by strategic prioritization of R&D, manufacturing footprint choices, and the ability to deliver integrated patient support. Companies that invest in robust clinical evidence, including long-term safety data and patient-reported outcomes, gain credibility with specialty clinicians and payers. Similarly, organizations that optimize formulation portfolios-balancing immediate-release options for rapid titration against extended-release or topical alternatives for adherence and tolerability-can differentiate on both clinical and commercial fronts.

Operational excellence in manufacturing and quality control is another decisive factor, as reliable supply and compliant production practices underpin trust among hospitals, pharmacies, and regulators. Partnerships with contract manufacturers, investments in modular or nearshore facilities, and flexible packaging solutions are common strategies to reduce lead-time risk and respond to tariff-driven cost pressures. Equally important are channel and access strategies: firms that cultivate relationships with hospital formulary committees, develop branded portals for direct-to-patient engagement, and leverage retail and online pharmacy networks demonstrate superior reach. Finally, corporate approaches to lifecycle management-encompassing patent strategy, generic competition planning, and label expansions-determine long-term resilience and shape investment priorities across the competitive set.

Actionable and integrated recommendations spanning evidence generation, supply resilience, formulation differentiation, channel orchestration, and stakeholder engagement to secure competitive advantage

Industry leaders should pursue a coordinated set of actions to convert clinical advances into durable commercial advantage while safeguarding access and supply. First, prioritize investments in evidence generation that address both clinical efficacy and real-world outcomes; pragmatic trials and registry data can influence formulary decisions and clinician adoption. Second, adopt supply chain diversification measures that include nearshoring, multiple qualified suppliers, and flexible manufacturing contracts to mitigate tariff and logistics risks. These operational moves will reduce vulnerability to policy shifts and improve responsiveness to demand fluctuations.

Third, design differentiated formulation and route-of-administration strategies that align with patient preferences and adherence patterns, leveraging extended-release and topical innovations where clinically appropriate. Fourth, build comprehensive channel strategies that integrate hospital pharmacy engagement with retail and online distribution, and develop branded portals to deliver education, adherence support, and access programs. Fifth, engage proactively with payers and regulators through transparent evidence sharing and early dialogue to shape reimbursement frameworks and label expansions. Finally, cultivate partnerships with specialty clinics, patient advocacy groups, and academic centers to co-develop education initiatives, expedite diagnostic pathways, and ensure patient-centric trial designs. Together, these recommendations provide a pragmatic roadmap for translating scientific opportunity into sustainable patient impact and commercial performance.

A rigorous mixed-methods research design integrating clinician interviews, supply chain expertise, literature synthesis, and scenario analysis to validate strategic findings

The research methodology underpinning this report combines qualitative and quantitative techniques to ensure robust, reproducible insights. Primary research included structured interviews with clinicians across dermatology and urology specialties, discussions with supply chain and regulatory experts, and consultations with distribution channel stakeholders. These engagements were designed to capture first-hand perspectives on clinical decision drivers, procurement practices, and patient access barriers, thereby anchoring the analysis in real-world experience.

Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and public filings to map the disease biology, therapeutic mechanisms, and policy environments. Data synthesis involved triangulating these inputs to validate trends, identify inflection points, and test strategic hypotheses. Scenario analysis and sensitivity checks were employed to explore how variations in tariff policy, channel mix, and formulation uptake could alter operational priorities. Throughout, emphasis was placed on transparency of assumptions, traceability of sources, and validation through expert review, ensuring the findings are credible and actionable for executives and clinical leaders planning next steps.

Strategic synthesis highlighting the convergent clinical, operational, and policy drivers that will determine future access and value capture for therapies addressing this rare endocrinological condition

In conclusion, the landscape surrounding 5-alpha reductase deficiency is evolving in ways that reward strategic alignment across clinical development, manufacturing, distribution, and payer engagement. Genetic and diagnostic progress, coupled with formulation innovations and shifting distribution models, are reshaping how therapies are developed, delivered, and adopted. At the same time, policy actions such as tariff changes and payer negotiation behavior require organizations to be agile in sourcing and contracting decisions to preserve access and margins.

Looking forward, success will favor stakeholders who invest in high-quality evidence, diversify manufacturing and supply strategies, and design patient-centered access models tailored to varying clinical settings and regional contexts. By implementing the recommendations outlined, industry leaders can enhance resilience, improve patient outcomes, and capture sustainable value in a nuanced and shifting ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. 5-Alpha Reductase Deficiency Market, by Treatment Type

  • 8.1. Dutasteride
  • 8.2. Finasteride

9. 5-Alpha Reductase Deficiency Market, by Formulation

  • 9.1. Capsule
    • 9.1.1. Extended Release
    • 9.1.2. Immediate Release
  • 9.2. Solution
    • 9.2.1. Concentrated
    • 9.2.2. Standard
  • 9.3. Tablet
    • 9.3.1. Extended Release
    • 9.3.2. Immediate Release

10. 5-Alpha Reductase Deficiency Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Topical

11. 5-Alpha Reductase Deficiency Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. 5-Alpha Reductase Deficiency Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Private
    • 12.1.2. Public
  • 12.2. Online Pharmacy
    • 12.2.1. Branded Portal
    • 12.2.2. Third-Party Marketplace
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain
    • 12.3.2. Independent

13. 5-Alpha Reductase Deficiency Market, by End User

  • 13.1. Clinics
    • 13.1.1. Dermatology
    • 13.1.2. Urology
  • 13.2. Home Care
    • 13.2.1. Caregiver-Administered
    • 13.2.2. Self-Administered
  • 13.3. Hospitals
    • 13.3.1. General
    • 13.3.2. Specialty

14. 5-Alpha Reductase Deficiency Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. 5-Alpha Reductase Deficiency Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. 5-Alpha Reductase Deficiency Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States 5-Alpha Reductase Deficiency Market

18. China 5-Alpha Reductase Deficiency Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies, Inc.
  • 19.6. Bio-Rad Laboratories, Inc.
  • 19.7. Cadila Healthcare Limited
  • 19.8. Danaher Corporation
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. Fulgent Genetics, Inc.
  • 19.11. Illumina, Inc.
  • 19.12. Invitae Corporation
  • 19.13. PerkinElmer, Inc.
  • 19.14. QIAGEN N.V.
  • 19.15. Sun Pharmaceutical Industries Ltd.
  • 19.16. Teva Pharmaceutical Industries Ltd.
  • 19.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 269. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 270. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 271. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 276. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)

TABLE